Project Grant K99MH137253
- This federal Project Grant award of $844,917 from the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants) aims to identify and characterize moderate effect size (MES) risk genes that contribute to the liability and presentation of Autism Spectrum Disorder (ASD). The key objectives are to: 1) Identify and characterize MES risk genes using rare and common genetic variation; 2) Identify MES risk genes on chromosome X; 3) Identify MES risk genes contributing to ASD...
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, will support a "Copy Number Variant Discovery Pipeline for Integrated Genome-Exome Sequencing" at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The $206,250 award, with a project period from September 1, 2025 to August 31, 2027, will fund research to systematically assess the impact of copy number...
- This $124,488 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, supports a study on mapping cell type-specific isoform diversity in the human brain to dissect the mechanisms of alternative splicing in autism spectrum disorder (ASD). The project will leverage long-read sequencing technology to fully interrogate the biological function of isoforms in neuropsychiatric disease, with the goal of revealing broader...
- The National Institute of Mental Health (NIMH) awarded a $183,118 Project Grant under the Mental Health Research Grants (CFDA 93.242) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to integrate genomic and electronic health record (EHR) data to accelerate precision psychiatry. The key products and services to be delivered include: Developing phenotyping algorithms to define clinically-relevant psychiatric traits, such as age at onset,...
- This Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) provides $182,851 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research on identifying deficient memory replay as a potentially treatable mechanism of impaired sleep-dependent memory consolidation in schizophrenia. The project aims to examine the contribution of hippocampal replay to sleep-dependent memory consolidation...
- This Project Grant award, totaling $735,932, was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program. The funding will support research conducted by St. Jude Children's Research Hospital Inc. to elucidate the cellular mechanisms underlying positive symptoms, such as auditory hallucinations, in mouse models of two strong genetic predictors of schizophrenia - 22q11.2 microdeletion syndrome and 3q29 microdeletion syndrome. The...
- This federal Project Grant award for $836,344 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will support research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the cellular and molecular mechanisms underlying neuroprogression in early-course psychosis. The key objectives are to leverage patient-derived stem cells to develop ex vivo assays that can mechanistically link...
- This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support a 4-year, $165,796 research project to investigate the impact of autism spectrum disorder (ASD) genetic risk on microglia function and neuronal interactions using human stem cell models. The project aims to leverage advances in human stem cell culture and 3D cortical spheroid models to assess how ASD-associated genetic mutations (CHD8 and...
- This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $194,375 to the University of Wisconsin-Madison to characterize the impact of midbody remnant-mediated genetic information transfer on cortical development in autism spectrum disorder (ASD). The research aims to elucidate how an ASD-associated PTEN mutation alters the molecular composition of midbody remnants (MBRs) and how MBR uptake...
- This federal Project Grant award of $742,484 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will fund a comprehensive research initiative to characterize a genetic mouse model and delineate its function in the brain. The project aims to obtain multiome single nucleus RNA-sequencing and ATAC-seq data, analyze and correlate the data sets, and examine chromatin state and brain morphology changes. Additionally, the project will...
This Project Grant award from the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants) provides $129,290 to The General Hospital Corporation (dba Massachusetts General Hospital) to conduct research on mapping the genotype to developmental course across the autism spectrum disorder (ASD) and schizophrenia (SCZ) gradient. The research aims to 1) distinguish subgroups of ASD children and SCZ adults based on behavioral/diagnostic trajectories and compare their clinical outcomes, 2) characterize the trajectory subgroups by genetic burdens and environmental exposures, and 3) evaluate the expression consequences of common genetic variation associated with intellectual disability, ASD, and SCZ in neuropsychiatric risk genes across developmental timepoints. This 2-year project, beginning in August 2025, leverages data from over 43,000 participants and 1,900 postmortem brain tissue donors to advance understanding of the neurodevelopmental gradient spanning intellectual disability, ASD, and SCZ.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $129.3k | 8/22/25 |